Cohen Capital Management Inc. Sells 43,846 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

Cohen Capital Management Inc. reduced its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 38.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 68,815 shares of the company’s stock after selling 43,846 shares during the period. Cohen Capital Management Inc.’s holdings in Elanco Animal Health were worth $833,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of ELAN. AM Squared Ltd bought a new stake in Elanco Animal Health during the third quarter valued at about $34,000. Wilmington Savings Fund Society FSB acquired a new position in shares of Elanco Animal Health during the third quarter worth approximately $35,000. Farther Finance Advisors LLC boosted its position in shares of Elanco Animal Health by 158.7% in the third quarter. Farther Finance Advisors LLC now owns 3,332 shares of the company’s stock valued at $49,000 after acquiring an additional 2,044 shares during the period. Venturi Wealth Management LLC grew its stake in shares of Elanco Animal Health by 89.9% in the third quarter. Venturi Wealth Management LLC now owns 3,382 shares of the company’s stock worth $50,000 after acquiring an additional 1,601 shares during the last quarter. Finally, Blue Trust Inc. raised its stake in Elanco Animal Health by 2,129.2% during the 3rd quarter. Blue Trust Inc. now owns 3,968 shares of the company’s stock valued at $57,000 after purchasing an additional 3,790 shares during the last quarter. 97.48% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. Barclays boosted their price objective on shares of Elanco Animal Health from $19.00 to $20.00 and gave the stock an “overweight” rating in a report on Friday, November 8th. UBS Group began coverage on Elanco Animal Health in a report on Monday, December 9th. They set a “buy” rating and a $18.00 price objective on the stock. Leerink Partners started coverage on shares of Elanco Animal Health in a report on Monday, December 2nd. They issued a “market perform” rating and a $14.00 price target on the stock. Leerink Partnrs raised shares of Elanco Animal Health to a “hold” rating in a report on Monday, December 2nd. Finally, Morgan Stanley lowered their target price on shares of Elanco Animal Health from $15.00 to $14.00 and set an “equal weight” rating on the stock in a research note on Wednesday, January 29th. One research analyst has rated the stock with a sell rating, four have given a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $16.00.

Elanco Animal Health Price Performance

NYSE:ELAN opened at $11.02 on Friday. The firm has a market cap of $5.45 billion, a PE ratio of 27.54, a price-to-earnings-growth ratio of 2.50 and a beta of 1.42. The company’s 50-day moving average price is $11.80 and its two-hundred day moving average price is $13.10. The company has a quick ratio of 1.31, a current ratio of 2.55 and a debt-to-equity ratio of 0.66. Elanco Animal Health Incorporated has a 12 month low of $10.77 and a 12 month high of $18.80.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.